Phosphagenics partner scores Indian coup
16 April, 2013 by Dylan Bushell-EmblingPhosphagenics’ (ASX:POH) Indian licensee has arranged to sell a diclofenac gel using TPM technology to Novartis India.
UWA licenses genetic drug tech to Sarepta
15 April, 2013 by Dylan Bushell-EmblingThe University of Western Australia has licensed technology covering a prospective treatment for severe muscle-wasting disease DMD to existing partner Sarepta.
UBI picks up Vic govt technology voucher
15 April, 2013 by Dylan Bushell-EmblingUniversal Biosensors (ASX:UBI) and six other companies have secured grants of up to $250K under the Victorian Government’s Technology Implementation Voucher program.
Alchemia SPP raises $2.75m
13 April, 2013 by Dylan Bushell-EmblingAlchemia (ASX:ACL) has wrapped up a capital raising round with an oversubscribed SPP, securing a total of $12.95m to help fund its metastatic colorectal cancer trial.
Mesoblast CEO wins pontifical council award
12 April, 2013 by Dylan Bushell-EmblingMesoblast (ASX:MSB) CEO Silviu Itescu has been named the first recipient of the Pontifical Council for Culture and Stem for Life Foundation’s Key Innovation Award.
Benitec appoints Kevin Buchi to board
12 April, 2013 by Dylan Bushell-Embling and Lauren DavisNew Benitec (ASX:BLT) board member Kevin Buchi said he was drawn to the company due to the potential of its trial-ready hepatitis C treatment candidate.
pSivida launches social media push
11 April, 2013 by Dylan Bushell-EmblingpSivida (ASX:PVA) has launched channels on each of the four major social networks to provide more outlets to communicate key information to investors.
Tax reform story not over for biotech industry
11 April, 2013Building on the success of the Research and Development (R&D) Tax Incentive, industry leaders are calling for further tax reform to provide incentives for innovative manufacturing and investment, according to the Biotechnology Industry Position Survey 2013.
Clinuvel’s EU application for Scenesse delayed
09 April, 2013 by Dylan Bushell-EmblingThe EMA has allocated more time to review Clinuvel’s (ASX:CUV) application for approval of Scenesse as an EPP treatment.
Four more surgeons cleared to use CardioCel
09 April, 2013 by Dylan Bushell-EmblingAllied Healthcare (ASX:AHZ) says five surgeons have now received early approval to use heart patch CardioCel under the TGA’s Authorized Prescriber Scheme.
Beyond the debate
09 April, 2013 by Graeme O'NeillA leading opponent of transgenic crops in Britain recants. But Australian scientists developing GM crops to help feed the world aren’t waiting for local anti-GM campaigners to see the scientific light.
McKeon Report echoes industry’s calls
09 April, 2013Amid the raft of federal government consultations and reviews in recent months - a record number of which impact biotechnology - the Strategic Review of Health and Medical Research in Australia has released its final report, echoing industry’s calls for commercialisation, clinical trials and IP support.
Australia’s first Biohackathon
09 April, 2013A Biohackathon will open up scientific problem solving to the public next week in Sydney.
Novogen reaches cancer drug milestone
09 April, 2013 by Dylan Bushell-EmblingNovogen (ASX:NRT) has revealed that one enantiomer of cancer drug candidate CS-6 appears many times more active against brain cancer than the reverse form.
Phosphagenics gets ethics nod for pain patch trial
08 April, 2013 by Dylan Bushell-EmblingPhosphagenics (ASX:POH) has received ethics approval for a clinical trial of the redesigned version of pain patch TPM-oxycodone.
